Thus, the molecular study of TP53 in del(5q) MDS patients is useful before therapy with lenalidomide, and patients harboring any TP53 alterations should be closely followed to promptly identify treatment failure, refractoriness and progression. The gene discussed is TP53; the disease is myelodysplastic syndrome.